Download PDF
Hamostaseologie 2004; 24(04): 234-241
DOI: 10.1055/s-0037-1619635
Original Article
Schattauer GmbH

Thrombophilie

Thrombophilia
I. Pabinger
1   Medizinische Klinik I, Abteilung für Hämatologie und Hämostaseologie, Wien, Österreich
› Author Affiliations
Further Information

Publication History

Publication Date:
03 February 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Es wird ein Überblick über Definitionen, Epidemiologie, Klinik der angeborenen, sowie klinisch relevanter erworbener Thrombophilien gegeben. Diagnostische und therapeutische Strategien werden aufgezeigt.

Summary

A survey on definitions, epidemiology, clinical manifestations of congenital thrombophilias and clinical relevant acquired thrombophilias is given. Diagnostic and therapeutical strategies are presented.

Schlüsselwörter

Thrombophilie - venöse Thrombose - Antithrombinmangel - Protein-C-Mangel - Protein-S-Mangel - Faktor-V-Leiden - Prothrombinvariation - Lupusantikoagulans

Keywords

Thrombophilia - venous thrombosis - antithrombin deficiency - protein C deficiency - protein S deficiency - factor V Leiden - prothrombin variation - lupus anticoagulant
 

  • Literatur

  • 1 Bertina RM, Koeleman BPC, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64.
    CrossrefPubMedGoogle Scholar
  • 2 Branson HE, Katz J, Marble R. et al. Inherited protein C deficiency and coumarin-responsive chronic relapsing purpura fulminans in a newborn infant. Lancet 1983; 2: 1165.
    PubMedGoogle Scholar
  • 3 Chowdury V, Lane DA, Mille B. et al. Homozygous antithrombin deficiency: report of two new cases (99Leu to Phe) associated with arterial and venous thrombosis. Thromb Haemost 1994; 72: 198.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Crowther MA, Ginsberg JS, Julian J. et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
    CrossrefPubMedGoogle Scholar
  • 5 Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004.
    CrossrefPubMedGoogle Scholar
  • 6 D’Angelo A, della Valle P, Crippa L. et al. Autoimmune protein S deficiency in a boy with severe thromboembolic disease. N Engl J Med 1993; 328: 1753-7.
    CrossrefPubMedGoogle Scholar
  • 7 De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996; 87: 3531-44.
    PubMedGoogle Scholar
  • 8 De Stefano V, Leone G, Matrangelo S. et al. Clinical manifestations and management of inherited thrombophilia: Retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein. Sem Thromb Haemost 1994; 72: 352.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Den Heijer M, Koster T, Blom HJ. et al. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. N Engl J Med 1996; 334: 759.
    CrossrefPubMedGoogle Scholar
  • 10 Dreyfus M, Magny FJ, Bridey F. et al. Treatment of homozygous protein C deficiency and neonatal purpura fulminans with a purified protein C concentrate. N Engl J Med 1991; 325: 1565.
    CrossrefPubMedGoogle Scholar
  • 11 Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965; 13: 516.
    PubMedGoogle Scholar
  • 12 Eichinger S, Pabinger I, Stümpflen A. et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Eichinger S, Stümpflen A, Hirschl M. et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Eichinger S, Schönauer V, Weltermann A. et al. Thrombin activatable fibrinolysis inhibitor (TAFI) and the risk of recurrent venous thrombosis. Blood 2004; 103: 3773-6.
    CrossrefPubMedGoogle Scholar
  • 15 Ehrenforth S, Nemes L, Mannhalter C. et al. Impact of environmental and hereditary risk factors on the manifestation of thrombophilia in homozygous carriers of factor V:G1691A. J Thromb Haemost 2004; 2: 430-6.
    CrossrefPubMedGoogle Scholar
  • 16 Falcon CR, Cattaneo M, Panzeri D. et al. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscler Thromb 1994; 14: 1080.
    CrossrefPubMedGoogle Scholar
  • 17 Frosst P, Blom HJ, Milos R. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genetics 1995; 10: 111-3.
    CrossrefPubMedGoogle Scholar
  • 18 Griffin J, Evatt B, Zimmerman T. et al. Deficiency of protein C in congenital thrombotic disease. J Clin Invest 1981; 68: 1370.
    CrossrefPubMedGoogle Scholar
  • 19 Heijboer H, Brandjes DPM, Buller HR. et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512.
    CrossrefPubMedGoogle Scholar
  • 20 Khamashta MA, Cuadrado MJ, Mujic F. et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
    CrossrefPubMedGoogle Scholar
  • 21 Koeleman BPC, Reitsma PH, Allaart CF. et al. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient patients. Blood 1994; 84: 1031.
    PubMedGoogle Scholar
  • 22 Koster T, Rosendaal FR, de Ronde H. et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503.
    CrossrefPubMedGoogle Scholar
  • 23 Koster T, Blann AD, Briet E. et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152.
    CrossrefPubMedGoogle Scholar
  • 24 Kyrle PA, Minar E, Hirschl M. et al. High plasma levels of factor VIII and the risk of recurrent venous thrombosis. N Engl J Med 2000; 343: 457-62.
    CrossrefPubMedGoogle Scholar
  • 25 Lane DA, Olds RJ, Boisclair M. et al. Antithrombin III mutation database: First update. Thromb Haemost 1993; 70: 361.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 26 Lechner K, Kyrle PA. Antithrombin III concentrates – are they clinically useful?. Thromb Haemost 1995; 73: 340-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Lechner K, Pabinger-Fasching I. Lupus anticoagulants and thrombosis. A study of 25 cases and review of the literature. Haemostasis 1985; 15: 254-62.
    PubMedGoogle Scholar
  • 28 Male C, Lechner K, Eichinger S. et al. Clinical significance of lupus anticoagulants in children. J Pediatr 1999; 134: 199.
    CrossrefPubMedGoogle Scholar
  • 29 Marlar RA, Montgomery RR, Madden RM. Homozygous protein C deficiency. In: Bertina RM. (ed). Protein C and related proteins. Edinburgh, UK: Churchill Livingstone; 1988: 182.
    Google Scholar
  • 30 Miletich J, Sherman L, Broze Jr. G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 17: 991.
    PubMedGoogle Scholar
  • 31 Mustafa S, Pabinger I, Mannhalter C. Protein S deficiency type I: identification of point mutations in 9 of 10 families. Blood 1995; 86: 3444.
    PubMedGoogle Scholar
  • 32 Pabinger I, Brucker S, Kyrle PA. et al. Hereditary deficiency of antithrombin III, protein C and protein S: Prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coagul Fibrinolysis 1992; 3: 547.
    CrossrefPubMedGoogle Scholar
  • 33 Pabinger I, Kyrle PA, Heistinger M. et al. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: A prospective cohort study. Thromb Haemost 1994; 71: 441.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 34 Pabinger I, Schneider B. the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71: 548.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 35 Pabinger I, Schneider B. the GTH Study Group on Natural Inhibitors. The thrombotic risk in hereditary antithrombin III-, protein C- and protein S-deficiency: a cooperative retrospective study. Arterioscler Thromb Vasc Biol 1996; 16: 742-8.
    CrossrefPubMedGoogle Scholar
  • 36 Palareti G, Legnani C, Cosmi B. et al. Risk of venous thromboembolism recurrence: high negative predictive value of D-dimer performed after oral anticoagulation is stopped. Thromb Haemost 2002; 87: 7-12.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 37 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3’ untranslated region of the prothrombin gene is associated with elevated plasma thrombin levels and an increase in venous thrombosis. Blood 1996; 10: 3698-703.
    PubMedGoogle Scholar
  • 38 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346: 1133.
    CrossrefPubMedGoogle Scholar
  • 39 Reitsma PH, Bernardi F, Doig RG. et al. Protein C deficiency:A database of mutations, 1995 update. Thromb Haemost 1995; 73: 876.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Ridker PM, Miletich JP, Stampfer MJ. et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
    CrossrefPubMedGoogle Scholar
  • 41 Rintelen C, Pabinger I, Knöbl P. et al. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-32.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 42 Rosendaal FR, Koster T, Vandenbroucke JP. et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504.
    PubMedGoogle Scholar
  • 43 Schafer AI. Bleeding and thrombosis in the myeloproliferative disorders. Blood 1984; 64: 1-12.
    PubMedGoogle Scholar
  • 44 Schwarz HP, Fischer M, Hopmeier P. et al. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297.
    PubMedGoogle Scholar
  • 45 Lindmarker P, Schulman S, Sten-Linder M. et al. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation. Thromb Haemost 1999; 81: 684.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 46 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330 (05) 17.
    PubMedGoogle Scholar
  • 47 Tait R, Walker ID, Perry DJ. et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106.
    CrossrefPubMedGoogle Scholar
  • 48 Tait RC, Walker ID, Reitsma PH. et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 1995; 73: 87.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 49 Thaler E, Balzar E, Kopsa H. et al. Acquired antithrombin III deficiency in patients with glomerular proteinuria. Haemostasis 1978; 7: 257-72.
    PubMedGoogle Scholar
  • 50 Thaler E, Lechner K. Antithrombin III deficiency and thromboembolism. Clin Haematol 1981; 10: 369-90.
    PubMedGoogle Scholar
  • 51 Triplett DA. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 1995; 78: 1-31.
    CrossrefPubMedGoogle Scholar
  • 52 Vandenbroucke JP, Koster T, Briet E. et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453.
    CrossrefPubMedGoogle Scholar
  • 53 Zöller B, Bernsdotter A, Garcia de Frutos P. et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518.
    PubMedGoogle Scholar